NCT04614636 2023-09-21
FT538 in Subjects With Advanced Hematologic Malignancies
Fate Therapeutics
Phase 1 Terminated
Clinical Trials
3 trialsNCT03104270 2022-03-31
Combination Study for High Risk Multiple Myeloma Patients
Oncotherapeutics
Phase 2 Terminated
NCT00726869 2012-08-23
A Phase 1/2, Multi-center, Open-label, Dose-escalation Study of Elotuzumab(Humanized Anti-CS1 Monoclonal IgG1 Antibody) and Bortezomib in Subjects With Multiple Myeloma Following One to Three Prior Therapies.
Abbott
Phase 1 Terminated